Developer docs
API playgroundTry for free, no card

Search company profiles

Alamar Biosciences

Full company profile

uuid00003y1

Namestring
Alamar Biosciences
Legal namestring
Alamar Biosciences, Inc.
Websiteurl
alamarbio.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Alamar Biosciences is a commercial-stage precision proteomics company that develops and sells the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) platform, an immunoassay technology that achieves attomolar sensitivity — roughly 10,000x more sensitive than traditional ELISA/PLA — by combining a sequential immunocomplex capture-and-release mechanism with NGS or qPCR readout. Its flagship instrument, the ARGO HT System, is a fully automated, high-throughput proteomics analyzer that processes up to 288 samples per run with under 30 minutes of hands-on time and integrates cloud-connected data analysis software.

The company monetizes through a razor-and-blade model: it sells ARGO HT instruments to pharmaceutical and biotech companies, academic medical centers, and research institutions, and generates recurring revenue from NULISAseq multiplex panels (Neuro 220, CNS Disease 120, Inflammation 250/250+, Mouse 120), NULISAqpcr single-plex and multiplex assays (BD-pTau217, NfL, AD 5-plex, IL-1B, IL-4), Dried Blood Spot extraction kits, and a Technology Access Program (TAP) for fee-for-service proof-of-concept work. Distribution is hybrid: direct enterprise sales in North America and major European markets, supplemented by exclusive regional distributors across APAC, EMEA, and LATAM, and a Certified Service Provider network of 11 partners including IQVIA Laboratories, Biognosys, and Frontage Labs.

Founded in 2018 in Fremont, California by the inventors of RNAscope technology, Alamar has scaled to over 300 customers across 25 countries with 100+ installed ARGO HT instruments, achieved ISO 13485 and SOC 2 compliance, and grew revenue from $25.1 million in 2024 to $74.2 million in 2025 (196% YoY). Following a $128 million Series C in 2024 and a $50+ million convertible note round in January 2026, the company completed its NASDAQ IPO (ticker ALMR) on April 17, 2026 at a $1.5 billion valuation, raising approximately $191.3 million in gross proceeds.

Short descriptiontext

Alamar Biosciences is a precision proteomics company whose NULISA platform and ARGO HT instrument enable attomolar-sensitivity multiplexed protein biomarker analysis for pharmaceutical, biotech, and academic research customers across 25 countries.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersFremont, United States
HQ citystring
Fremont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision proteomics, protein biomarker detection, ultra-sensitive immunoassays, multiplexed proteomic panels, proteomics instrumentation
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Proteomics Instrumentation
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1ARGO HT Instrument Sales
TypeHardware Sales
Description

Sale of the ARGO HT automated proteomics instrument - a fully integrated qPCR system enabling sample-to-data workflows. Each instrument generates over $400,000 in average annual consumables pull-through, representing a land-and-expand model with high LTV.

aijourn.com
2NULISAseq Panel Consumables
TypeSubscription Recurring
Description

Recurring revenue from multiplexed assay panels including Neuro 220, CNS Disease Panel 120, Inflammation Panel 250, and Inflammation Panel AQ. Consumables revenue grew 178% year-over-year in Q1 2026, indicating strong recurring demand.

aijourn.com
3NULISAqpcr Assay Consumables
TypeSubscription Recurring
Description

Single-plex and 5-plex qPCR-based assays including BD-pTau217, NfL, AD 5-plex, and custom assays. Consumables revenue grew 178% YoY in Q1 2026.

aijourn.com
4Technology Access Program (TAP)
TypeProfessional Services
Description

Fee-for-service model providing proof-of-concept data using NULISA assays before customers purchase the ARGO HT system. Includes Pro Services (full service analysis) and Custom Assay Development services.

alamarbio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1ARGO HT System instrument
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

No publicly disclosed pricing. Instruments sold directly with 1-year warranty included. Field Service Engineer installation and training provided.

alamarbio.com
2NULISAseq Panels (Neuro 220, CNS 120, Inflammation 250/250+, Mouse 120)
ModelSubscriptionBilling cadenceAnnual
Notes

No publicly disclosed pricing. Recurring consumables revenue model with subscription-like repeat purchases from installed instrument base.

alamarbio.com
3NULISAqpcr Assays (BD-pTau217, NfL, IL-4, IL-1B, AD 5-plex)
ModelSubscriptionBilling cadenceAnnual
Notes

No publicly disclosed pricing. Single-plex format runs 74 samples, 5-plex runs 84 samples per 96-well plate.

alamarbio.com
4Technology Access Program (TAP) Services
ModelOtherBilling cadencePay-as-you-go
Notes

Fee-for-service model for proof-of-concept testing. Includes Pro Services (consultation, sample analysis, bioinformatics support up to 40 hrs) and Custom Assay Development.

alamarbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1NULISA
Description

Ultra-high sensitivity proteomics platform technology enabling attomolar-level protein detection with high multiplexing capabilities

alamarbio.com
+4 more records
Core offering1 text field

Alamar Biosciences develops and commercializes the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) proteomics platform alongside the ARGO HT automated instrument system. The company sells multiplexed assay panels (NULISAseq) and single-plex qPCR assays (NULISAqpcr) for ultra-high sensitivity detection of protein biomarkers in research applications targeting neurology, immunology, and oncology. Products are sold to pharmaceutical companies, biotech firms, academic medical centers, and contract research organizations across more than 25 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 10,000x sensitivity improvement over traditional PLA and ELISA technologies
+5 more records
Product overview1 text field

Alamar Biosciences offers a platform-based portfolio centered on the NULISA technology and ARGO HT System. The NULISA Platform provides ultra-high sensitivity proteomics with attomolar detection and high multiplexing through proprietary sequential immunocomplex capture combined with NGS/qPCR readout. The ARGO HT System serves as the core automated instrument enabling sample-to-data workflows. The product portfolio includes NULISAseq multiplex panels (Neuro 220, CNS Disease Panel 120, Inflammation Panel 250, Inflammation Panel AQ, Mouse Panel 120) for multi-biomarker profiling, NULISAqpcr single-plex and 5-plex assays (AD 5-plex, BD-pTau217, NfL) for targeted biomarker quantification, the NULISA Dried Blood Spot Extraction Kit for remote sampling, and NULISAqpcr Custom Assay Development for bespoke biomarker panels. Software solutions (ARGO Command Center, NULISA Analysis Software, NULISAseqR R package) support data analysis. Services include the Technology Access Program for proof-of-concept studies and a network of Certified Service Providers for outsourced proteomics.

Product and service13 records
1ARGO HT System
CategoryAutomated Proteomics Instrument
Description

Fully automated, high-throughput precision proteomics instrument performing ultra-high sensitivity and multiplexed protein analysis. Integrates sample preparation, qPCR/NGS readout, and data analysis in one compact system, processing up to 288 samples per run batch with under 30 minutes hands-on time. Designed for pharma/biotech and academic research institutions.

2NULISAseq Neuro 220 Panel
CategoryMultiplexed Assay Panel
Description

Multiplexed proteomics panel measuring 220 biomarkers from a single 10 µL sample, covering Alzheimer's, Parkinson's, TBI, ALS, MS, and Gliomas. Includes 12 highly specific assays for Tau protein isoforms (pTau217, pTau181, pTau205, pTau212, pTau231) and 25 Parkinson's disease biomarkers developed with the Michael J. Fox Foundation. Targets neuroscience researchers and drug developers.

3NULISAseq CNS Disease Panel 120
CategoryMultiplexed Assay Panel
Description

Multiplexed panel enabling ultra-sensitive quantification of 120+ neuro-specific and inflammatory proteins from 10 µL plasma or CSF. Includes brain-derived Tau isoforms (pTau217, pTau181, pTau231, tTau) for comprehensive tau pathology assessment from blood. Targets CNS disease researchers and translational scientists.

4NULISAseq Inflammation Panel 250
CategoryMultiplexed Assay Panel
Description

Comprehensive inflammatory response panel measuring 250+ proteins from 10 µL sample with attomolar sensitivity. Detects baseline levels of low-abundance cytokines for early detection of disease signatures across autoimmune, neuroinflammatory, and immune-oncology research. For immunology and inflammation researchers.

5NULISAseq Inflammation Panel AQ
CategoryMultiplexed Assay Panel
Description

Quantifies 250+ biomarkers with absolute quantitation for 150+ targets. Ultra-high fg/mL sensitivity detects biomarker levels in normal, baseline, and disease samples. Designed for longitudinal tracking and clinical cohort studies in immunology research.

6NULISAseq Mouse Panel 120
CategoryMultiplexed Assay Panel
Description

Multiplexed panel of 120+ proteins designed specifically for murine experiments. Broadest coverage of immunology and only panel to include neurology content. Attomolar sensitivity detects low-abundant targets such as p-tau217 for pre-clinical studies. For pre-clinical and translational animal model researchers.

7NULISAqpcr AD 5-plex Assay
CategoryMultiplexed qPCR Assay
Description

Research-use-only multiplexed assay measuring five Alzheimer's blood-based biomarkers (BD-pTau217, NfL, Aβ42, GFAP, APOE4) from a single plasma sample. Consolidates multiple single-plex tests with enhanced sensitivity and streamlined workflow for Alzheimer's research.

8NULISAqpcr BD-pTau217 Assay
CategorySingle-Plex qPCR Assay
Description

Single-plex assay for precise detection of brain-derived pTau217 in blood or CSF using 10 µL sample. Uniquely specific to low molecular weight pTau217 isoform from CNS. fg/mL sensitivity with 7-point standard curve for absolute quantitation. For Alzheimer's researchers.

9NULISAqpcr NfL Assay
CategorySingle-Plex qPCR Assay
Description

Single-plex assay for precise detection of neurofilament light protein in serum or plasma. Attomolar sensitivity enables early neuroaxonal injury detection and monitoring across ALS, Alzheimer's, Parkinson's, MS, TBI, and stroke. For neurology researchers.

10NULISA Dried Blood Spot Extraction Kit
CategorySample Preparation Kit
Description

Standardized workflow for recovering protein analytes from dried blood and plasma spots. Validated across Capitainer, Telimmune, Mitra, Tasso, and Whatman devices with 85-95% target detectability using 96-well filter-plate format for high-throughput processing. Enables decentralized, longitudinal, and population-scale research studies.

11NULISAqpcr Custom Assay Development
CategoryCustom Assay Development Service
Description

Custom biomarker assay development service using NULISAqpcr technology. Researchers provide their own antibodies to create tailored assays with attomolar sensitivity. Requires 100 µg antibody input per target, generating enough material for 3,500+ samples. For researchers with specialized biomarker needs.

12Alamar Analysis Solutions
CategoryData Analysis Software
Description

Integrated data analysis software suite including ARGO Command Center (cloud-based run setup and QC), NULISA Analysis Software (QC, normalization, statistical analysis), and NULISAseqR R package for advanced bioinformatics. Supports proteomics data interpretation for ARGO HT users.

13Technology Access Program (TAP)
CategoryProteomics Service Program
Description

Fee-for-service program providing researchers access to ultra-high sensitivity NULISA multiplex and single-plex assays for proof-of-concept data before purchasing the ARGO HT System. Includes Pro Services (full sample analysis with consultation and bioinformatics support up to 40 hours) and Custom Assay Development.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Sanofi joined Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study as newest partner. Alamar's NULISA technology is part of this study platform for biomarker analysis.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

BEVIMI will conduct a randomized, placebo-controlled clinical study utilizing Alamar's next-generation inflammatory biomarker panel to assess Uno Protect brain health formulation safety and biomarker responses.

3The Michael J. Fox Foundation for Parkinson's Research
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Collaboration supporting development of the NULISAseq Neuro 220 Panel, which includes 15 new Parkinson's disease biomarkers and 12 Tau protein isoform assays developed in collaboration with MJFF.

biospace.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Certified Service Provider offering development, validation and implementation of multiplexed assays using NULISA platform for biopharma customers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Certified Service Provider offering specialty proteomics services combining mass spectrometry with NULISA multiplex assays.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Certified Service Provider offering biomarker assay development, validation, and sample analysis services.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Exclusive distributor for Australia and New Zealand, providing local sales and support for NULISA and ARGO HT products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Exclusive distributor for Singapore, providing local sales and support for Alamar products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Exclusive distributor for Japan, providing local sales and support for NULISA and ARGO HT products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Exclusive distributor for India, providing local sales and support for Alamar products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Exclusive distributor for South Korea, providing local sales and support.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Exclusive distributor for Czech Republic, Slovakia, Poland, and Hungary.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Exclusive distributor for Sao Paulo, Brazil, covering South America.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Strategic collaboration to join Bio-Hermes studies (Bio-Hermes-001 and Bio-Hermes-002) comparing blood-based and digital biomarkers across diverse populations. Alamar gains access to biospecimens and data from over 1,000 participants, contributing its NULISA proteomics technology to the research platform.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Olink's proximity extension assay (PEA) platform is Alamar's most direct competitor in high-multiplex protein biomarker detection. Acquired by Thermo Fisher Scientific in 2024 for ~$3.1B, the combination creates a peer with massive scale, established pharma relationships, and bundled instrument pricing that competes head-to-head with NULISA in neurodegenerative and inflammation research.

TypeDirect peer
Description

SomaLogic's SomaScan aptamer-based platform measures 7,000+ proteins from a single sample and is the broadest-multiplex direct competitor to NULISAseq. Alamar's CSO Steve Williams was previously CMO at SomaLogic, and the two platforms compete for pharma biomarker discovery budgets.

TypeDirect peer
Description

Quanterix's Simoa single-molecule array technology provides ultra-sensitive single-plex and multiplex protein detection, particularly strong in neurology (NfL, pTau) research. Direct competitor in the ultra-high-sensitivity biomarker segment where NULISAqpcr assays overlap, especially for Alzheimer's blood-based biomarkers.

TypeEmerging player
Description

Seer's Proteograph platform uses engineered nanoparticle-based enrichment with mass spectrometry for unbiased proteomics, targeting biomarker discovery at depth. Less directly overlapping than Olink or SomaLogic, but competes for the same pharma translational proteomics budget.

TypeEmerging player
Description

Nautilus is developing a single-molecule proteomics platform aiming to measure the full proteome. While still pre-commercial, it represents a long-term competitive threat to NULISA's high-multiplex, ultra-sensitive positioning if it achieves commercial scale.

TypeBroad incumbent
Description

10x Genomics sells Chromium and Xenium platforms for single-cell genomics and spatial biology, increasingly expanding into multi-omics including protein readout. Highly relevant as Alamar's CFO Justin McAnear was previously CFO at 10x and led its 2019 IPO, and both target overlapping translational research customers.

TypeBroad incumbent
Description

Bio-Techne is a diversified life sciences tools company offering Proteome Profiler arrays, ELISA kits, and Luminex-based multiplex assays. It serves overlapping pharma/biotech and academic customers with broader proteomics reagent menus but at lower sensitivity than NULISA's attomolar platform.

TypeBroad incumbent
Description

Bruker's timsTOF and other mass spectrometry platforms power proteomics workflows including those run by Biognosys (an Alamar CSP partner). Competes for translational proteomics research dollars, especially where unbiased discovery rather than targeted multiplex panels is required.

TypeOthers
Description

Illumina is both a sequencing platform provider that NULISAseq multiplex workflows depend on (NextSeq, NovaSeq validated configurations) and an investor via Illumina Ventures. Critical infrastructure partner whose sequencing reagent pricing and roadmap directly impact Alamar's multiplex panel economics.

TypeOthers
Description

Element's AVITI sequencing platform is validated for NULISAseq readout, providing Alamar with a non-Illumina sequencing option. Relevant as an alternative-NGS partner that diversifies Alamar's ecosystem dependency and reflects the broader sequencing landscape the platform navigates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration10 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alamar Biosciences

Precision Proteomics Instrumentationalamarbio.com

Alamar Biosciences is a precision proteomics company whose NULISA platform and ARGO HT instrument enable attomolar-sensitivity multiplexed protein biomarker analysis for pharmaceutical, biotech, and academic research customers across 25 countries.

What Alamar Biosciences does

Alamar Biosciences is a commercial-stage precision proteomics company that develops and sells the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) platform, an immunoassay technology that achieves attomolar sensitivity — roughly 10,000x more sensitive than traditional ELISA/PLA — by combining a sequential immunocomplex capture-and-release mechanism with NGS or qPCR readout. Its flagship instrument, the ARGO HT System, is a fully automated, high-throughput proteomics analyzer that processes up to 288 samples per run with under 30 minutes of hands-on time and integrates cloud-connected data analysis software.

The company monetizes through a razor-and-blade model: it sells ARGO HT instruments to pharmaceutical and biotech companies, academic medical centers, and research institutions, and generates recurring revenue from NULISAseq multiplex panels (Neuro 220, CNS Disease 120, Inflammation 250/250+, Mouse 120), NULISAqpcr single-plex and multiplex assays (BD-pTau217, NfL, AD 5-plex, IL-1B, IL-4), Dried Blood Spot extraction kits, and a Technology Access Program (TAP) for fee-for-service proof-of-concept work. Distribution is hybrid: direct enterprise sales in North America and major European markets, supplemented by exclusive regional distributors across APAC, EMEA, and LATAM, and a Certified Service Provider network of 11 partners including IQVIA Laboratories, Biognosys, and Frontage Labs.

Founded in 2018 in Fremont, California by the inventors of RNAscope technology, Alamar has scaled to over 300 customers across 25 countries with 100+ installed ARGO HT instruments, achieved ISO 13485 and SOC 2 compliance, and grew revenue from $25.1 million in 2024 to $74.2 million in 2025 (196% YoY). Following a $128 million Series C in 2024 and a $50+ million convertible note round in January 2026, the company completed its NASDAQ IPO (ticker ALMR) on April 17, 2026 at a $1.5 billion valuation, raising approximately $191.3 million in gross proceeds.

Alamar Biosciences firmographics

Firmographics
Name
Alamar Biosciences
Legal name
Alamar Biosciences, Inc.
Website
https://alamarbio.com
Company type
Public
Founded year
2018
Operating status
Ipo
Headcount range
251–500 employees
Short description
Alamar Biosciences is a precision proteomics company whose NULISA platform and ARGO HT instrument enable attomolar-sensitivity multiplexed protein biomarker analysis for pharmaceutical, biotech, and academic research customers across 25 countries.
Ownership category
akta.pro rank

Alamar Biosciences industry classification

Industry
Product category
Precision Proteomics Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Precision proteomics
  • Protein biomarker detection
  • Ultra-sensitive immunoassays
  • Multiplexed proteomic panels
  • Proteomics instrumentation

Where Alamar Biosciences is headquartered

Location

Headquarters

HQ city
Fremont
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alamar Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. ARGO HT Instrument Sales: Sale of the ARGO HT automated proteomics instrument - a fully integrated qPCR system enabling sample-to-data workflows. Each instrument generates over $400,000 in average annual consumables pull-through, representing a land-and-expand model with high LTV.
  2. NULISAseq Panel Consumables: Recurring revenue from multiplexed assay panels including Neuro 220, CNS Disease Panel 120, Inflammation Panel 250, and Inflammation Panel AQ. Consumables revenue grew 178% year-over-year in Q1 2026, indicating strong recurring demand.
  3. NULISAqpcr Assay Consumables: Single-plex and 5-plex qPCR-based assays including BD-pTau217, NfL, AD 5-plex, and custom assays. Consumables revenue grew 178% YoY in Q1 2026.
  4. Technology Access Program (TAP): Fee-for-service model providing proof-of-concept data using NULISA assays before customers purchase the ARGO HT system. Includes Pro Services (full service analysis) and Custom Assay Development services.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractARGO HT System instrument
SubscriptionAnnualNULISAseq Panels (Neuro 220, CNS 120, Inflammation 250/250+, Mouse 120)
SubscriptionAnnualNULISAqpcr Assays (BD-pTau217, NfL, IL-4, IL-1B, AD 5-plex)
OtherPay-as-you-goTechnology Access Program (TAP) Services

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Alamar Biosciences product offering

Product offering

Core offering

Alamar Biosciences develops and commercializes the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) proteomics platform alongside the ARGO HT automated instrument system. The company sells multiplexed assay panels (NULISAseq) and single-plex qPCR assays (NULISAqpcr) for ultra-high sensitivity detection of protein biomarkers in research applications targeting neurology, immunology, and oncology. Products are sold to pharmaceutical companies, biotech firms, academic medical centers, and contract research organizations across more than 25 countries.

Product overview

Alamar Biosciences offers a platform-based portfolio centered on the NULISA technology and ARGO HT System. The NULISA Platform provides ultra-high sensitivity proteomics with attomolar detection and high multiplexing through proprietary sequential immunocomplex capture combined with NGS/qPCR readout. The ARGO HT System serves as the core automated instrument enabling sample-to-data workflows. The product portfolio includes NULISAseq multiplex panels (Neuro 220, CNS Disease Panel 120, Inflammation Panel 250, Inflammation Panel AQ, Mouse Panel 120) for multi-biomarker profiling, NULISAqpcr single-plex and 5-plex assays (AD 5-plex, BD-pTau217, NfL) for targeted biomarker quantification, the NULISA Dried Blood Spot Extraction Kit for remote sampling, and NULISAqpcr Custom Assay Development for bespoke biomarker panels. Software solutions (ARGO Command Center, NULISA Analysis Software, NULISAseqR R package) support data analysis. Services include the Technology Access Program for proof-of-concept studies and a network of Certified Service Providers for outsourced proteomics.

Differentiator

Problem solved

Functional benefit

Brands

  • NULISA: Ultra-high sensitivity proteomics platform technology enabling attomolar-level protein detection with high multiplexing capabilities
  • ARGO HT
  • NULISAseq
  • NULISAqpcr
  • TAP (Technology Access Program)

Products and services

  • ARGO HT System Fully automated, high-throughput precision proteomics instrument performing ultra-high sensitivity and multiplexed protein analysis. Integrates sample preparation, qPCR/NGS readout, and data analysis in one compact system, processing up to 288 samples per run batch with under 30 minutes hands-on time. Designed for pharma/biotech and academic research institutions.
  • NULISAseq Neuro 220 Panel Multiplexed proteomics panel measuring 220 biomarkers from a single 10 µL sample, covering Alzheimer's, Parkinson's, TBI, ALS, MS, and Gliomas. Includes 12 highly specific assays for Tau protein isoforms (pTau217, pTau181, pTau205, pTau212, pTau231) and 25 Parkinson's disease biomarkers developed with the Michael J. Fox Foundation. Targets neuroscience researchers and drug developers.
  • NULISAseq CNS Disease Panel 120 Multiplexed panel enabling ultra-sensitive quantification of 120+ neuro-specific and inflammatory proteins from 10 µL plasma or CSF. Includes brain-derived Tau isoforms (pTau217, pTau181, pTau231, tTau) for comprehensive tau pathology assessment from blood. Targets CNS disease researchers and translational scientists.
  • NULISAseq Inflammation Panel 250 Comprehensive inflammatory response panel measuring 250+ proteins from 10 µL sample with attomolar sensitivity. Detects baseline levels of low-abundance cytokines for early detection of disease signatures across autoimmune, neuroinflammatory, and immune-oncology research. For immunology and inflammation researchers.
  • NULISAseq Inflammation Panel AQ Quantifies 250+ biomarkers with absolute quantitation for 150+ targets. Ultra-high fg/mL sensitivity detects biomarker levels in normal, baseline, and disease samples. Designed for longitudinal tracking and clinical cohort studies in immunology research.
  • NULISAseq Mouse Panel 120 Multiplexed panel of 120+ proteins designed specifically for murine experiments. Broadest coverage of immunology and only panel to include neurology content. Attomolar sensitivity detects low-abundant targets such as p-tau217 for pre-clinical studies. For pre-clinical and translational animal model researchers.
  • NULISAqpcr AD 5-plex Assay Research-use-only multiplexed assay measuring five Alzheimer's blood-based biomarkers (BD-pTau217, NfL, Aβ42, GFAP, APOE4) from a single plasma sample. Consolidates multiple single-plex tests with enhanced sensitivity and streamlined workflow for Alzheimer's research.
  • NULISAqpcr BD-pTau217 Assay Single-plex assay for precise detection of brain-derived pTau217 in blood or CSF using 10 µL sample. Uniquely specific to low molecular weight pTau217 isoform from CNS. fg/mL sensitivity with 7-point standard curve for absolute quantitation. For Alzheimer's researchers.
  • NULISAqpcr NfL Assay Single-plex assay for precise detection of neurofilament light protein in serum or plasma. Attomolar sensitivity enables early neuroaxonal injury detection and monitoring across ALS, Alzheimer's, Parkinson's, MS, TBI, and stroke. For neurology researchers.
  • NULISA Dried Blood Spot Extraction Kit Standardized workflow for recovering protein analytes from dried blood and plasma spots. Validated across Capitainer, Telimmune, Mitra, Tasso, and Whatman devices with 85-95% target detectability using 96-well filter-plate format for high-throughput processing. Enables decentralized, longitudinal, and population-scale research studies.
  • NULISAqpcr Custom Assay Development Custom biomarker assay development service using NULISAqpcr technology. Researchers provide their own antibodies to create tailored assays with attomolar sensitivity. Requires 100 µg antibody input per target, generating enough material for 3,500+ samples. For researchers with specialized biomarker needs.
  • Alamar Analysis Solutions Integrated data analysis software suite including ARGO Command Center (cloud-based run setup and QC), NULISA Analysis Software (QC, normalization, statistical analysis), and NULISAseqR R package for advanced bioinformatics. Supports proteomics data interpretation for ARGO HT users.
  • Technology Access Program (TAP) Fee-for-service program providing researchers access to ultra-high sensitivity NULISA multiplex and single-plex assays for proof-of-concept data before purchasing the ARGO HT System. Includes Pro Services (full sample analysis with consultation and bioinformatics support up to 40 hours) and Custom Assay Development.

Quantifiable outcome

  • 10,000x sensitivity improvement over traditional PLA and ELISA technologies
  • +5 more outcomes

Companies that use Alamar Biosciences

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Alamar Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability2 records

Feature6 records

Alamar Biosciences partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • SanoficoreStrategic or Co-development Partner · 18 May 2026Sanofi joined Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study as newest partner. Alamar's NULISA technology is part of this study platform for biomarker analysis.
  • BEVIMIminorStrategic or Co-development Partner · 13 May 2026BEVIMI will conduct a randomized, placebo-controlled clinical study utilizing Alamar's next-generation inflammatory biomarker panel to assess Uno Protect brain health formulation safety and biomarker responses.
  • The Michael J. Fox Foundation for Parkinson's ResearchcoreStrategic or Co-development Partner · 17 March 2026Collaboration supporting development of the NULISAseq Neuro 220 Panel, which includes 15 new Parkinson's disease biomarkers and 12 Tau protein isoform assays developed in collaboration with MJFF.
  • IQVIA LaboratoriescoreChannel Partner/ Reseller/ Distributor · 23 February 2026Certified Service Provider offering development, validation and implementation of multiplexed assays using NULISA platform for biopharma customers.
  • BiognosyscoreChannel Partner/ Reseller/ Distributor · 23 February 2026Certified Service Provider offering specialty proteomics services combining mass spectrometry with NULISA multiplex assays.
  • Frontage LabscoreChannel Partner/ Reseller/ Distributor · 23 February 2026Certified Service Provider offering biomarker assay development, validation, and sample analysis services.
  • GeneWorkscoreChannel Partner/ Reseller/ Distributor · 23 February 2026Exclusive distributor for Australia and New Zealand, providing local sales and support for NULISA and ARGO HT products.
  • GenomaxcoreChannel Partner/ Reseller/ Distributor · 23 February 2026Exclusive distributor for Singapore, providing local sales and support for Alamar products.
  • Scrum, Inc.coreChannel Partner/ Reseller/ Distributor · 23 February 2026Exclusive distributor for Japan, providing local sales and support for NULISA and ARGO HT products.
  • SpincocoreChannel Partner/ Reseller/ Distributor · 23 February 2026Exclusive distributor for India, providing local sales and support for Alamar products.
  • PhileKoreacoreChannel Partner/ Reseller/ Distributor · 23 February 2026Exclusive distributor for South Korea, providing local sales and support.
  • GeneTiCA GroupcoreChannel Partner/ Reseller/ Distributor · 23 February 2026Exclusive distributor for Czech Republic, Slovakia, Poland, and Hungary.
  • PensabiocoreChannel Partner/ Reseller/ Distributor · 23 February 2026Exclusive distributor for Sao Paulo, Brazil, covering South America.
  • Global Alzheimer's Platform FoundationcoreStrategic or Co-development Partner · 9 January 2026Strategic collaboration to join Bio-Hermes studies (Bio-Hermes-001 and Bio-Hermes-002) comparing blood-based and digital biomarkers across diverse populations. Alamar gains access to biospecimens and data from over 1,000 participants, contributing its NULISA proteomics technology to the research platform.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Alamar Biosciences competitors and assessment

Company assessment

Direct peers

  • Olink Holding (Thermo Fisher Scientific): Olink's proximity extension assay (PEA) platform is Alamar's most direct competitor in high-multiplex protein biomarker detection. Acquired by Thermo Fisher Scientific in 2024 for ~$3.1B, the combination creates a peer with massive scale, established pharma relationships, and bundled instrument pricing that competes head-to-head with NULISA in neurodegenerative and inflammation research.
  • SomaLogic (Standard BioTools): SomaLogic's SomaScan aptamer-based platform measures 7,000+ proteins from a single sample and is the broadest-multiplex direct competitor to NULISAseq. Alamar's CSO Steve Williams was previously CMO at SomaLogic, and the two platforms compete for pharma biomarker discovery budgets.
  • Quanterix: Quanterix's Simoa single-molecule array technology provides ultra-sensitive single-plex and multiplex protein detection, particularly strong in neurology (NfL, pTau) research. Direct competitor in the ultra-high-sensitivity biomarker segment where NULISAqpcr assays overlap, especially for Alzheimer's blood-based biomarkers.

Emerging players

  • Seer: Seer's Proteograph platform uses engineered nanoparticle-based enrichment with mass spectrometry for unbiased proteomics, targeting biomarker discovery at depth. Less directly overlapping than Olink or SomaLogic, but competes for the same pharma translational proteomics budget.
  • Nautilus Biotechnology: Nautilus is developing a single-molecule proteomics platform aiming to measure the full proteome. While still pre-commercial, it represents a long-term competitive threat to NULISA's high-multiplex, ultra-sensitive positioning if it achieves commercial scale.

Broad incumbents

  • 10x Genomics: 10x Genomics sells Chromium and Xenium platforms for single-cell genomics and spatial biology, increasingly expanding into multi-omics including protein readout. Highly relevant as Alamar's CFO Justin McAnear was previously CFO at 10x and led its 2019 IPO, and both target overlapping translational research customers.
  • Bio-Techne: Bio-Techne is a diversified life sciences tools company offering Proteome Profiler arrays, ELISA kits, and Luminex-based multiplex assays. It serves overlapping pharma/biotech and academic customers with broader proteomics reagent menus but at lower sensitivity than NULISA's attomolar platform.
  • Bruker: Bruker's timsTOF and other mass spectrometry platforms power proteomics workflows including those run by Biognosys (an Alamar CSP partner). Competes for translational proteomics research dollars, especially where unbiased discovery rather than targeted multiplex panels is required.

Others

  • Illumina: Illumina is both a sequencing platform provider that NULISAseq multiplex workflows depend on (NextSeq, NovaSeq validated configurations) and an investor via Illumina Ventures. Critical infrastructure partner whose sequencing reagent pricing and roadmap directly impact Alamar's multiplex panel economics.
  • Element Biosciences: Element's AVITI sequencing platform is validated for NULISAseq readout, providing Alamar with a non-Illumina sequencing option. Relevant as an alternative-NGS partner that diversifies Alamar's ecosystem dependency and reflects the broader sequencing landscape the platform navigates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Alamar Biosciences social profiles

Digital presence

Alamar Biosciences compliance and trust

Trust signal

Compliance2 records

Alamar Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alamar Biosciences leadership team

Management profile

Number of profiles

Profiles12 records

Alamar Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alamar Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alamar Biosciences

What does Alamar Biosciences do?

Alamar Biosciences develops and commercializes the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) proteomics platform alongside the ARGO HT automated instrument system. The company sells multiplexed assay panels (NULISAseq) and single-plex qPCR assays (NULISAqpcr) for ultra-high sensitivity detection of protein biomarkers in research applications targeting neurology, immunology, and oncology. Products are sold to pharmaceutical companies, biotech firms, academic medical centers, and contract research organizations across more than 25 countries.

Is Alamar Biosciences a public or private company?

Alamar Biosciences is a public company. It is classified as public and is currently ipo.

When was Alamar Biosciences founded?

Alamar Biosciences was founded in 2018. It employs 251 to 500 people.

Where is Alamar Biosciences based?

Alamar Biosciences is headquartered in Fremont, United States, in the North America region.

How does Alamar Biosciences make money?

Four revenue lines are on record. ARGO HT Instrument Sales are the primary driver. The others are NULISAseq Panel Consumables, NULISAqpcr Assay Consumables and technology Access Program (TAP).

Who are Alamar Biosciences's main competitors?

Direct peers on record are Olink Holding (Thermo Fisher Scientific), SomaLogic (Standard BioTools) and Quanterix. Emerging players are Seer and Nautilus Biotechnology. Broad incumbents are 10x Genomics, Bio-Techne and Bruker. Others are Illumina and Element Biosciences.

Does Alamar Biosciences have an API?

No public API is recorded for Alamar Biosciences.

What industry is Alamar Biosciences in?

Alamar Biosciences's product category is Precision Proteomics Instrumentation. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DevdiscourseHEALTH ROUNDS-New blood test measures Alzheimer's progressionResearchers reported a new blood test from Alamar Biosciences that measures eMTBR-tau, a biomarker reflecting tau protein tangle buildup in Alzheimer's disease. The test is not yet available for clinical use and is not meant to diagnose on its own. A separate study found that cerebrospinal fluid flow declines with age, possibly linked to neurodegenerative disorder risk.Stock TitanAlamar Biosciences NULISA data in 46 CTAD presentationsAlamar Biosciences announced its NULISA platform data will be featured in 46 presentations, including 10 oral, at CTAD 2026 in Boston. The data cover therapeutic response, fluid biomarkers, and new biology, with results from Johnson & Johnson's Phase 2 Autonomy trial and others.The future of tradingQiming Corporate GP VI, Affiliates Report Sale of $2.94 Million in Alamar Biosciences Common SharesQiming affiliates sold 100,117 Alamar Biosciences common shares on November 11, 2026, at $29.34 and $30.63 per share. Combined holdings fell to 8,995,481 shares, per the Form 4 filed November 13, 2026.Seeking AlphaAlamar Biosciences, Inc. (ALMR) Presents at 2026 UBS Global Healthcare Conference TranscriptAlamar Biosciences reported Q4 revenue up 68% and consumables up 79% at its 2026 UBS Healthcare Conference call. Gross margin reached a record 61.5%, and the company announced a collaboration with the U.K. Biobank and GSK. It also raised its 2026 revenue outlook.TradingViewTD Cowen maintains Alamar Biosciences at Buy, raises price target to $36 from $34TD Cowen maintained Alamar Biosciences at Buy and raised its price target to $36 from $34, a 5.9% increase. The target implies an upside of 19.1% from the Nov 3 close of $30.22.TradingViewAlamar Biosciences 3Q 2026: Revenue $33.5M, Net loss $13.3M, EPS $(0.19) — 10-Q SummaryAlamar Biosciences reported third-quarter 2026 revenue of $33.5M, up 68% year-over-year, while net loss widened to $13.3M. Diluted EPS was $(0.19), down from $(0.69) a year earlier. The company plans to submit its ARGO HT/DX to the FDA for marketing authorization in 2027.MarketScreenerAlamar Biosciences Partners with GSK on Large-Scale Proteomic StudyAlamar Biosciences will use its Nulisa platform to collaborate with GSK on a large-scale proteomic study of circulating protein signatures. The study will analyze over 60,000 serum samples across respiratory, liver, kidney, neurological, and autoimmune conditions to advance precision prevention and earlier disease detection.MorningstarAlamar Biosciences Partners with GSK on Large-Scale Proteomic StudyAlamar Biosciences announced a partnership with GSK to study circulating protein signatures and disease progression using its Nulisa platform. The study will analyze over 60,000 serum samples across respiratory, liver, kidney, neurological, and autoimmune conditions to advance precision prevention and earlier detection.TradingViewAlamar Biosciences Partners with GSK on Large-Scale Proteomic StudyAlamar Biosciences will use its Nulisa platform to collaborate with GSK on a large-scale proteomic study of circulating protein signatures. The study will analyze over 60,000 serum samples across respiratory, liver, kidney, neurological, and autoimmune conditions to advance precision prevention and earlier disease detection.MarketWatchAlamar Biosciences Partners with GSK on Large-Scale Proteomic StudyAlamar Biosciences will use its Nulisa platform to collaborate with GSK on a large-scale proteomic study of circulating protein signatures. The study will analyze over 60,000 serum samples across respiratory, liver, kidney, neurological, and autoimmune conditions to advance precision prevention and earlier disease detection.